Vonoprazan fumarate for the management of acid-related diseases.

about

Vonoprazan fumarate for the management of acid-related diseases.

Item

http://www.wikidata.org/entity/Q39402205

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Vonoprazan fumarate for the management of acid-related diseases.

@en

Vonoprazan fumarate for the management of acid-related diseases.

@nl

type

Item

label

Vonoprazan fumarate for the management of acid-related diseases.

@en

Vonoprazan fumarate for the management of acid-related diseases.

@nl

prefLabel

Vonoprazan fumarate for the management of acid-related diseases.

@en

Vonoprazan fumarate for the management of acid-related diseases.

@nl

P1476

Vonoprazan fumarate for the management of acid-related diseases.

@en

P2093

Edoardo Savarino

http://www.w3.org/2001/XMLSchema#string

Irene Martinucci

http://www.w3.org/2001/XMLSchema#string

Nicola de Bortoli

http://www.w3.org/2001/XMLSchema#string

Santino Marchi

http://www.w3.org/2001/XMLSchema#string

Vincenzo Savarino

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

Vonoprazan: first global approval.

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.

Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).

The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy.

Novel approaches to the pharmacological blockade of gastric acid secretion.

Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.

Acid suppression therapy: where do we go from here?

Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.

P304

1145-1152

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1346087

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elisa Marabotto

Corrado Blandizzi

Giorgia Bodini

P577

2017-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28657473

http://www.w3.org/2001/XMLSchema#string